The nephSAP editorial team and the KSAP editorial board extend their sincere appreciation to the following reviewers. Their efforts and insights help improve the quality of these postgraduate education offerings.

**nephSAP Review Panel, Volume 22, Number 1, April 2023**

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/University</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josephine Abraham, MD, MPH, FASN</td>
<td>University of Utah</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Olufemi A. Aduroja, MD, FASN</td>
<td>Texas Tech University Health Sciences Center El Paso</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Taha Ayach, MD, FASN</td>
<td>University of Kentucky</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Shweta Bansal, MD, MBBS, FASN</td>
<td>University of Texas Health at San Antonio</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Nadiesda Costa, MD, MPH, FASN</td>
<td>Georgetown University</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Steven M. Gorbatkin, MD, PhD, FASN</td>
<td>University of Washington</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Susan Grossman, MD</td>
<td>Brooklyn VA</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Aijaz A. Gundroo, MD, FASN</td>
<td>The Ohio State University Wexner Medical Center</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Swapnil Hiremath, MD, MPH, FASN</td>
<td>University of Ottawa</td>
<td>CANADA</td>
</tr>
<tr>
<td>Nithin Karakala, MD, FASN</td>
<td>University of Arkansas for Medical Sciences</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Elizabeth A. Kendrick, MD, FASN</td>
<td>UCLA Health</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Daphne Harrington Knicely, MD, FASN</td>
<td>Johns Hopkins University School of Medicine</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Paul A. Kovach, MD, FASN</td>
<td>Columbus Nephrology, Inc.</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>David J. Leehey, MD</td>
<td>Loyola University Medical Center</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Rajil B. Mehta, MD, FASN</td>
<td>Starzl Transplantation Institute</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Georges Nakhoul, MD, FASN</td>
<td>Cleveland Clinic Foundation</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Robert Nee, MD, FASN</td>
<td>Walter Reed National Military Medical Center</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Sankar Narayan Niranjan, MD, FASN</td>
<td>Greater Hartford Nephrology</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Nirupama Ramkumar, MD, MPH, FASN</td>
<td>University of Utah</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Rupam Ruchi, MD, FASN</td>
<td>University of Florida</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Gurmukteshwar Singh, MD, FASN</td>
<td>Geisinger Medical Center- Nephrology</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>James Sondheimer</td>
<td>Wayne State University</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Ekamol Tantisattamo, MD, FASN, MPH</td>
<td>University of California, Irvine School of Medicine</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Ravi K. Thimmisetty, MD, FASN</td>
<td>Ochsner Clinic Foundation</td>
<td>UNITED STATES</td>
</tr>
<tr>
<td>Ruth L. Wintz, MD, FASN</td>
<td>Kidney Associates</td>
<td>UNITED STATES</td>
</tr>
</tbody>
</table>
Learning Objectives

1. To discuss recent developments in the diagnosis, monitoring, and therapy of CKD - mineral and bone disorder.
2. To describe new developments in calcium and phosphate physiology and pathophysiology, with updates on recent information regarding derangements of mineral metabolism in normal and decreased kidney function.
3. To explain bone disease including osteoporosis and renal osteodystrophy.
4. To summarize new information regarding disorders of magnesium, calcium, and vitamin D metabolism, including primary hyperparathyroidism.
5. To examine recent updates in the causes, diagnosis, and therapy of hypercalcemia.
6. To review recent advances in kidney stone disease.

Target Audience:
Physicians, scientists, advanced practitioners, nurses, pharmacists, and other health professionals working and training in the field of nephrology.

Accreditation Statement

In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians: The American Society of Nephrology designates this enduring material for a maximum of 10.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to Joint Accreditation for the purpose of granting ABIM MOC credit.

MOC points will be applied to only those ABIM candidates who have enrolled in the MOC program. It is your responsibility to complete the ABIM MOC enrollment process.

Original Release Date
April 2023

CME/MOC Termination Date
March 31, 2025 at 11:59 pm ET

Examination Available Online
On or before April 30, 2023

Estimated Time for Completion
10 hours

Self-Assessment Examination
- Answers with explanations are provided with a passing score after the first and/or second attempt.
- This issue will be archived on April 1, 2025, and answers with explanations will be posted on the ASN website.
Method of Participation

- Read the entire issue that is supplemented by original articles in the reference lists.
- Complete the online self-assessment examination.
- Each participant is allowed two attempts to pass the examination (75% correct) for CME and MOC.
- Upon completion, review your score and incorrect answers and print your certificate.

Activity Evaluation, CE, and MOC

1. Go to the ASN eLEARNING CENTER (education.asn-online.org)
2. Select MY ACTIVITIES from the left-hand navigation.
3. Select the corresponding issue.
4. Read all information on the Overview screen.
5. Follow the onscreen instructions to:
   a. Complete the Exam (i.e., post test),
   b. Complete the Evaluation,
   c. Claim credit/MOC
      i. IMPORTANT: select the credit type that corresponds with your designation, and
   d. Print a Certificate

Your ASN Transcript is available on the ASN website
- Go to the ASN website and log in to your ASN Profile page: https://www.asn-online.org/myasn/profile.aspx
- Select the CME/CE Transcript tab
- View credits claimed or print a certificate with continuing education information for completed learning activities

System Requirements

Compatible Browser and Software
The nephSAP website (nephSAP.org) is formatted for cross-browser functionality and should display correctly in all currently supported web browsers. Individual nephSAP articles are available as dynamic HTML or in Portable Document Format (PDF), which requires Adobe Reader or comparable PDF viewing software.

Monitor Settings
The nephSAP website was designed to be viewed in a 1024 × 768 or higher resolution.

Medium or Combination of Media Used
The media used include content provided online as dynamic HTML or downloadable PDF, in addition to an online evaluation and self-assessment examination.

Technical Support
If you have difficulty viewing any of the pages, please refer to the nephSAP technical support page for possible solutions. If you continue having problems, contact ASN at nephsap@asn-online.org.
ASNDisclosure Policy

It is the policy of American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN’s educational activities are expected to disclose all their and their lifespouse/partner’s financial relationships with “ineligible companies” within the prior 24 months as well as other non-financial interests. (“Ineligible companies” are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients.) Participants should note that the use of products outside US Food and Drug Administration (FDA) approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications.

The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in educational activities, but rather to ensure that these activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.

ASN requires all individuals in a position to control content for this activity to complete disclosure forms on the ASN website. Responses are listed below. Disclosures have been reviewed and assessed by ASN. All relationships with ineligible companies have been identified and all relevant financial relationships have been mitigated.

EDITORS:
Alice M. Sheridan, MD—Employer(s): Brigham and Women’s Hospital; No additional relevant financial relationship(s) with ineligible companies to disclose.
Martina M. McGrath, MBChB, FASN—Employer(s): Brigham and Women’s Hospital; VA Boston Medical Center; No additional relevant financial relationship(s) with ineligible companies to disclose.

EDITORIAL AUTHOR:
Grahame Elder, MBBS, PhD—Employer(s): Westmead Hospital, NSW, Australia; University of Notre Dame, NSW, Australia; Garvan Institute of Medical Research, NSW, Australia; No additional relevant financial relationship(s) with ineligible companies to disclose.

AUTHORS:
Matthew J. Damasiewicz, MBBS—Employer(s): Monash Medical Centre; No additional relevant financial relationship(s) with ineligible companies to disclose.
Ana Carina Ferreira, DrMed—Employer(s): Centro Hospitalar e Universitário de Lisboa Central - Hospital Curry Cabral; Consultancy: Viphor; Honoraria: Viphor, Amgen; Advisory or Leadership Role: Portuguese Society of Nephrology (unpaid)
Anibal Ferreira, MD—Employer(s): Vascular Access Center of Nephrocare Lumiar
Rosa M.A. Moyzes, MD, PhD—Employer(s): Nephrology Division, Universidade de Sao Paulo; Honoraria: Lectures for Amgen, Accord; Other Interests or Relationships: Departamento de Metabolismo Mineral da Sociedade Brasileira de Nefrologia
Thomas Nickolas, MD, MS—Employer(s): Columbia University; Consultancy: Pharmacosmos, Alnylam; Research Funding: Amgen; Honoraria: Pharmacosmos, Alnylam; Patents or Royalties: Columbia University has licensed patents on NGAL to Abbott Diagnostics and Alera; Advisory or Leadership Role: Amgen, Pharmacosmos
Sagar U. Nigwekar, MD, MMSc—Employer(s): Massachusetts General Hospital; Consultancy: Fresenius Medical Therapies Group, Epizon Pharma, Laboratory Sanifit, Inozyme Pharma, CSL Vifor; Research Funding: Hope Pharma, Alnylam, Laboratory Sanifit, Inozyme Pharma; Honoraria: Inozyme Pharma, Guidepoint; Patents or Royalties: UpToDate
Jason R. Stubbs, MD—Employer(s): University of Kansas Medical Center
Silvia Titan, MD, PhD—Employer(s): Mayo Clinic
Jaime Uribarri, MD—Employer(s): Icahn School of Medicine at Mount Sinai, New York, NY
Carsten A. Wagner, DrMed, MD—Employer(s): University of Zurich; Consultancy: Ardelyx, Medice, Chugai, Kyowa Kirin; Research Funding: Chugai; Honoraria: Medice, Kyowa Kirin, Salmon Pharma; Advisory or Leadership Role: ERA Scientific Advisory Board (Chair)
James B. Wetmore, MD, MS—Employer(s): Hennepin Healthcare; Consultancy: Ad hoc consulting for BMS-Pfizer Alliance; Research Funding: NIH (NIDDK and NHLBI), AstraZeneca; OPKO Health; Merck; Genentech, Amgen, BMS/Pfizer, GlaxoSmithKline; Honoraria: BMS-Pfizer Alliance, Vifor; Other Interests or Relationships: Honoraria for educational activities (CME-eligible) for nephSAP (ASN) and Healio
ASN STAFF: Suzanne P. Armstrong, MA—Employer(s): American Society of Nephrology; No additional relevant financial relationship(s) with ineligible companies to disclose.

Commercial Support
There is no commercial support for this issue.